Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
复制标题
DOI：
10.1017/s1461145713001119
复制
发表时间：
2014-02
期刊：
影响因子：
--
通讯作者：
Mathew SJ
中科院分区：
文献类型：
--
作者：
Haile CN;Murrough JW;Iosifescu DV;Chang LC;Al Jurdi RK;Foulkes A;Iqbal S;Mahoney JJ 3rd;De La Garza R 2nd;Charney DS;Newton TF;Mathew SJ
氯胺酮在难治性抑郁症（TRD）中产生快速的抗抑郁作用，但个体患者之间的反应程度差异很大。脑源性神经营养因子（BDNF）已被研究为抑郁症治疗反应的生物标志物，并与氯胺酮的作用机制有关。我们评估了22例TRD患者的血浆BDNF及其与症状的相关性，这些患者参加了一项氯胺酮与麻醉剂对照（咪达唑仑）的随机对照试验。氯胺酮在输注后240分钟显著增加了应答者与非应答者的血浆BDNF水平，并且蒙哥马利-卡斯伯格抑郁评定量表（MADRS）评分与BDNF呈负相关（r=-0.701，p=0.008）。输注后240 min的血浆BDNF水平与240 min（r=-0.897，p= 0.002）、24 h（r=-0.791，p=0.038）、48 h（r=-0.944，p=0.001）和72 h（r=-0.977，p=0.010）的MADRS评分高度负相关。未发现接受咪达唑仑治疗的患者与BDNF相关。这些数据支持血浆BDNF作为与氯胺酮抗抑郁反应相关的外周生物标志物。
Ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), but the magnitude of response varies considerably between individual patients. Brain-derived neurotrophic factor (BDNF) has been investigated as a biomarker of treatment response in depression and has been implicated in the mechanism of action of ketamine. We evaluated plasma BDNF and associations with symptoms in 22 patients with TRD enrolled in a randomized controlled trial of ketamine compared to an anaesthetic control (midazolam). Ketamine significantly increased plasma BDNF levels in responders compared to non-responders 240 min post-infusion, and Montgomery–Åsberg Depression Rating Scale (MADRS) scores were negatively correlated with BDNF (r=–0.701, p=0.008). Plasma BDNF levels at 240 min post-infusion were highly negatively associated with MADRS scores at 240 min (r=–0.897, p=.002), 24 h (r=–0.791, p=0.038), 48 h (r=–0.944, p=0.001) and 72 h (r=–0.977, p=0.010). No associations with BDNF were found for patients receiving midazolam. These data support plasma BDNF as a peripheral biomarker relevant to ketamine antidepressant response.